By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Spark Therapeutics 

3737 Market Street
Suite 1300
Philadelphia  Pennsylvania  10104  U.S.A.
Phone: 888-772-7560 Fax: n/a


Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first approved treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.

Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.

Spark is based in Philadelphia, PA and was spun out of The Children's Hospital of Philadelphia in October 2013. In May 2014, Spark announced the completion of a $72.8 million Series B financing led by Sofinnova Ventures, bringing the company's total funding raised to $82.8 million to-date. To learn more about Spark visit

Key Statistics

Ownership: Public

Web Site: Spark Therapeutics
Employees: n/a
Symbol: ONCE


Company News
Spark Therapeutics (ONCE) Reports Second Quarter 2015 Results 8/5/2015 7:49:00 AM
Spark Therapeutics (ONCE) To Host Conference Call On August 5th At 8:30a.M. To Discuss Second Quarter 2015 Results 7/29/2015 8:55:38 AM
Spark Therapeutics (ONCE) To Present With Pfizer (PFE) Preclinical Data On Their Lead SPK-FIX Product Candidate For Hemophilia B At The 2015 International Society Of Thrombosis And Haemostasis Congress In June 6/19/2015 7:32:02 AM
Spark Therapeutics (ONCE) To Participate In Two International Conferences In London In June 6/17/2015 1:12:15 PM
Spark Therapeutics (ONCE) Reports First Quarter 2015 Results 5/6/2015 7:59:06 AM
Spark Therapeutics (ONCE) To Have Multiple Presentations At 2015 Association for Research in Vision & Ophthalmology Meeting 5/1/2015 10:24:56 AM
Spark Therapeutics (ONCE) To Host Conference Call On May 6th At 8:30a.M. To Discuss First Quarter 2015 Results 5/1/2015 8:42:13 AM
Spark Therapeutics (ONCE) And Clearside Biomedical Announce Exclusive Option To License Technology For Potentially Differentiated Delivery Of Gene Therapy To The Eye 4/29/2015 6:55:09 AM
Spark Therapeutics (ONCE) To Ring The Nasdaq Stock Market Opening Bell 3/30/2015 3:55:03 PM
Spark Therapeutics (ONCE) Reports Full Year 2014 Financial Results 3/18/2015 7:45:15 AM